688613.SHG Allgens Medical Technology Co. Ltd. A
- Market cap
- CNY 1.20B
- P/E
- 145.8x
- P/B
- 1.04x
- ROE
- 0.4%
- Dividend yield
- 0.19%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688613.SHG undervalued?
Graham number688613.SHG trades 159.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Allgens Medical Technology Co. Ltd. A fundamental analysis
No fundamental analysis for Allgens Medical Technology Co. Ltd. A yet.
Allgens Medical Technology Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Allgens Medical Technology Co. Ltd. A
Allgens Medical Technology CO., LTD. engages in the research and development, production, and sale of biomedical materials and related medical device products in China. The company offers biomimetic mineralized collagen artificial bone repair products, including Gejin, Chibei, and Lurui, as well as Aoyu Ning; tissue regeneration and repair products; and absorbable collagen hemostatic sponge products. Its products include isometal, cranial ulcer, teeth, dental implants, and b…
Full company profileAllgens Medical Technology Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Allgens Medical Technology Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 91.4M | 124M | 169M | 184M | 236M | 245M | 226M | 206M | 224M | 208M |
| Gross Profit | 72.8M | 103M | 140M | 154M | 200M | 205M | 187M | 147M | 224M | 132M |
| Operating Income | 27.5M | 34.8M | 74.4M | 102M | 135M | 96.3M | 49.0M | -7.36M | 12.6M | -6.13M |
| EBITDA | 32.1M | 40.2M | 86.1M | 115M | 146M | 112M | 67.0M | 11.1M | 29.9M | 3.96M |
| Net Income | 23.5M | 33.0M | 67.8M | 88.9M | 121M | 95.2M | 54.2M | -12.7M | 13.2M | 5.51M |
| EPS | 0.29 | 0.34 | 0.68 | 0.89 | 1.01 | 0.71 | 0.41 | -0.09 | 0.10 | 0.04 |
| Balance Sheet | ||||||||||
| Total Assets | 320M | 525M | 716M | 805M | 1.43B | 1.46B | 1.53B | 1.54B | 1.56B | 1.52B |
| Total Liabilities | 8.27M | 73.4M | 152M | 153M | 155M | 133M | 123M | 119M | 117M | 73.5M |
| Shareholders' Equity | 312M | 438M | 533M | 623M | 1.24B | 1.30B | 1.38B | 1.40B | 1.43B | 1.44B |
| Cash & Short-term Investments | 13.0M | 86.2M | 455M | 492M | 1.07B | 1.08B | 1.06B | 1.05B | 169M | 98.7M |
| Total Debt | - | - | 46.5M | 52.1M | 80.6M | 61.6M | 53.4M | 52.4M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 33.2M | 79.7M | 88.4M | 84.9M | 130M | 102M | 51.7M | -19.6M | 39.5M | - |
| Capital Expenditure | 30.6M | 99.5M | 77.1M | 56.4M | 61.2M | 45.4M | 21.9M | 13.4M | 28.9M | 10.1M |
| Free Cash Flow | 2.54M | -19.8M | 11.3M | 28.5M | 68.5M | 56.6M | 29.8M | -33.0M | 10.6M | -113M |
| Ratios | ||||||||||
| ROE | 7.5% | 7.5% | 12.7% | 14.3% | 9.7% | 7.3% | 3.9% | -0.9% | 0.9% | 0.4% |
| ROA | 7.3% | 6.3% | 9.5% | 11.0% | 8.5% | 6.5% | 3.6% | -0.8% | 0.8% | 0.4% |
| Net Profit Margin | 25.8% | 26.7% | 40.2% | 48.4% | 51.2% | 38.8% | 23.9% | -6.1% | 5.9% | 2.6% |
| Debt to Equity | - | - | 0.09x | 0.08x | 0.06x | 0.05x | 0.04x | 0.04x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Allgens Medical Technology Co. Ltd. A dividends
- Dividend yield
- 0.19%
- Forward dividend
- 0.03 CNY
- Payout ratio
- 17.3%
- Ex-dividend date
- Aug 6, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 2.28M | 0.02 | 17.3% |
| 2024 | CNY 10.8M | 0.08 | - |
| 2023 | CNY 14.0M | 0.11 | 25.9% |
| 2022 | CNY 36.3M | 0.27 | 38.1% |
| 2021 | CNY 1.24M | 0.01 | 1.0% |
| 2020 | CNY 1.40M | 0.01 | 1.6% |
| 2019 | CNY 1.68M | 0.02 | 2.5% |
| 2018 | - | - | - |
| 2017 | 311K | 0.00 | 1.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Allgens Medical Technology Co. Ltd. A
- Insiders 30.96%
- Institutions 4.49%
- Public & others 64.55%
- Shares outstanding 137M
- Free float 99.4M
Allgens Medical Technology Co. Ltd. A company profile
- Company name
- Allgens Medical Technology Co. Ltd. A
- Ticker
- 688613.SHG
- ISIN
- CNE1000051W7
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 271
- Fiscal year end
- December
- Address
- 3rd Floor, Building 35, Phase 2, Beijing, China, 102609
- Phone
- 86 10 5633 0938
- Website
- allgensmed.cn
About Allgens Medical Technology Co. Ltd. A
Allgens Medical Technology CO., LTD. engages in the research and development, production, and sale of biomedical materials and related medical device products in China. The company offers biomimetic mineralized collagen artificial bone repair products, including Gejin, Chibei, and Lurui, as well as Aoyu Ning; tissue regeneration and repair products; and absorbable collagen hemostatic sponge products. Its products include isometal, cranial ulcer, teeth, dental implants, and bongold. The company was founded in 2004 and is based in Beijing, China.
Allgens Medical Technology Co. Ltd. A management
6- Ms. Wanlan HuangFounder & Chairman · born 1943
- Mr. Zhiye QiuGM, Board Secretary & Director · born 1984
- Ms. Ling WangFinancial Officer · born 1978
- Mr. Tianxi SongDeputy GM & Director · born 1981
- Mr. Guofeng TianDeputy GM & Director · born 1982
- Xiaoying MiaoAccounting Supervisor